The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: A case study.

The World Health Organization (WHO) defines an effective round of mass drug administration (MDA) for lymphatic filariasis (LF) as one that reaches at least 65% of the target population. In its first round of MDA in 2011-2012, the National Program to Eliminate LF in Haiti achieved a 79% epidemiologic...

Full description

Bibliographic Details
Main Authors: Breanna K Wodnik, Didié Hérold Louis, Michel Joseph, Lee T Wilkers, Susan D Landskroener, Luccene Desir, Jean Frantz Lemoine, James V Lavery
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-05-01
Series:PLoS Neglected Tropical Diseases
Online Access:https://doi.org/10.1371/journal.pntd.0008318
id doaj-0de7112875ff44e893ff0b46f9ec3f36
record_format Article
spelling doaj-0de7112875ff44e893ff0b46f9ec3f362021-03-03T07:56:23ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352020-05-01145e000831810.1371/journal.pntd.0008318The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: A case study.Breanna K WodnikDidié Hérold LouisMichel JosephLee T WilkersSusan D LandskroenerLuccene DesirJean Frantz LemoineJames V LaveryThe World Health Organization (WHO) defines an effective round of mass drug administration (MDA) for lymphatic filariasis (LF) as one that reaches at least 65% of the target population. In its first round of MDA in 2011-2012, the National Program to Eliminate LF in Haiti achieved a 79% epidemiological coverage in urban Port-au-Prince. In 2013, coverage dropped below the WHO threshold and has declined year-over-year to a low of 41% in 2017. We conducted a retrospective qualitative case study to identify key factors behind the decline in coverage in Port-au-Prince and ways to address them. Our findings suggest that the main contributors to the decline in MDA coverage appear to be the absence of effective documentation of practices, reporting, analysis, and program quality improvement-i.e., learning mechanisms-within the program's MDA design and implementation strategy. In addition to their contribution to the program's failure to meet its coverage targets, these deficits have resulted in a high cost for the MDA campaign in both lost momentum and depleted morale. Through a proposed operating logic model, we explore how the pathway from program inputs to outcomes is influenced by a wide array of mediating factors, which shape potential participants' experience of MDA and, in turn, influence their reasoning and decisions to take, or not take, the pills. Our model suggests that the decisions and behavior of individuals are a reflection of their overall experience of the program itself, mediated through a host of contextual factors, and not simply the expression of a fixed choice or preference. This holistic approach offers a novel and potentially valuable framing for the planning and evaluation of MDA strategies for LF and other diseases, and may be applicable in a variety of global health programs.https://doi.org/10.1371/journal.pntd.0008318
collection DOAJ
language English
format Article
sources DOAJ
author Breanna K Wodnik
Didié Hérold Louis
Michel Joseph
Lee T Wilkers
Susan D Landskroener
Luccene Desir
Jean Frantz Lemoine
James V Lavery
spellingShingle Breanna K Wodnik
Didié Hérold Louis
Michel Joseph
Lee T Wilkers
Susan D Landskroener
Luccene Desir
Jean Frantz Lemoine
James V Lavery
The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: A case study.
PLoS Neglected Tropical Diseases
author_facet Breanna K Wodnik
Didié Hérold Louis
Michel Joseph
Lee T Wilkers
Susan D Landskroener
Luccene Desir
Jean Frantz Lemoine
James V Lavery
author_sort Breanna K Wodnik
title The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: A case study.
title_short The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: A case study.
title_full The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: A case study.
title_fullStr The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: A case study.
title_full_unstemmed The roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in Port-au-Prince, Haiti: A case study.
title_sort roles of stakeholder experience and organizational learning in declining mass drug administration coverage for lymphatic filariasis in port-au-prince, haiti: a case study.
publisher Public Library of Science (PLoS)
series PLoS Neglected Tropical Diseases
issn 1935-2727
1935-2735
publishDate 2020-05-01
description The World Health Organization (WHO) defines an effective round of mass drug administration (MDA) for lymphatic filariasis (LF) as one that reaches at least 65% of the target population. In its first round of MDA in 2011-2012, the National Program to Eliminate LF in Haiti achieved a 79% epidemiological coverage in urban Port-au-Prince. In 2013, coverage dropped below the WHO threshold and has declined year-over-year to a low of 41% in 2017. We conducted a retrospective qualitative case study to identify key factors behind the decline in coverage in Port-au-Prince and ways to address them. Our findings suggest that the main contributors to the decline in MDA coverage appear to be the absence of effective documentation of practices, reporting, analysis, and program quality improvement-i.e., learning mechanisms-within the program's MDA design and implementation strategy. In addition to their contribution to the program's failure to meet its coverage targets, these deficits have resulted in a high cost for the MDA campaign in both lost momentum and depleted morale. Through a proposed operating logic model, we explore how the pathway from program inputs to outcomes is influenced by a wide array of mediating factors, which shape potential participants' experience of MDA and, in turn, influence their reasoning and decisions to take, or not take, the pills. Our model suggests that the decisions and behavior of individuals are a reflection of their overall experience of the program itself, mediated through a host of contextual factors, and not simply the expression of a fixed choice or preference. This holistic approach offers a novel and potentially valuable framing for the planning and evaluation of MDA strategies for LF and other diseases, and may be applicable in a variety of global health programs.
url https://doi.org/10.1371/journal.pntd.0008318
work_keys_str_mv AT breannakwodnik therolesofstakeholderexperienceandorganizationallearningindecliningmassdrugadministrationcoverageforlymphaticfilariasisinportauprincehaitiacasestudy
AT didieheroldlouis therolesofstakeholderexperienceandorganizationallearningindecliningmassdrugadministrationcoverageforlymphaticfilariasisinportauprincehaitiacasestudy
AT micheljoseph therolesofstakeholderexperienceandorganizationallearningindecliningmassdrugadministrationcoverageforlymphaticfilariasisinportauprincehaitiacasestudy
AT leetwilkers therolesofstakeholderexperienceandorganizationallearningindecliningmassdrugadministrationcoverageforlymphaticfilariasisinportauprincehaitiacasestudy
AT susandlandskroener therolesofstakeholderexperienceandorganizationallearningindecliningmassdrugadministrationcoverageforlymphaticfilariasisinportauprincehaitiacasestudy
AT luccenedesir therolesofstakeholderexperienceandorganizationallearningindecliningmassdrugadministrationcoverageforlymphaticfilariasisinportauprincehaitiacasestudy
AT jeanfrantzlemoine therolesofstakeholderexperienceandorganizationallearningindecliningmassdrugadministrationcoverageforlymphaticfilariasisinportauprincehaitiacasestudy
AT jamesvlavery therolesofstakeholderexperienceandorganizationallearningindecliningmassdrugadministrationcoverageforlymphaticfilariasisinportauprincehaitiacasestudy
AT breannakwodnik rolesofstakeholderexperienceandorganizationallearningindecliningmassdrugadministrationcoverageforlymphaticfilariasisinportauprincehaitiacasestudy
AT didieheroldlouis rolesofstakeholderexperienceandorganizationallearningindecliningmassdrugadministrationcoverageforlymphaticfilariasisinportauprincehaitiacasestudy
AT micheljoseph rolesofstakeholderexperienceandorganizationallearningindecliningmassdrugadministrationcoverageforlymphaticfilariasisinportauprincehaitiacasestudy
AT leetwilkers rolesofstakeholderexperienceandorganizationallearningindecliningmassdrugadministrationcoverageforlymphaticfilariasisinportauprincehaitiacasestudy
AT susandlandskroener rolesofstakeholderexperienceandorganizationallearningindecliningmassdrugadministrationcoverageforlymphaticfilariasisinportauprincehaitiacasestudy
AT luccenedesir rolesofstakeholderexperienceandorganizationallearningindecliningmassdrugadministrationcoverageforlymphaticfilariasisinportauprincehaitiacasestudy
AT jeanfrantzlemoine rolesofstakeholderexperienceandorganizationallearningindecliningmassdrugadministrationcoverageforlymphaticfilariasisinportauprincehaitiacasestudy
AT jamesvlavery rolesofstakeholderexperienceandorganizationallearningindecliningmassdrugadministrationcoverageforlymphaticfilariasisinportauprincehaitiacasestudy
_version_ 1714826964406108160